AntiplateletHealthAgriloilNCT07784166
In Vivo Evaluation of Anti-inflammatory and Antithrombotic Health Promoting Properties of Extra Virgin Olive Oil Versus Classic Table Olive Oil in Healthy Subjects
A study testing Olive Oil 1 and Olive Oil 2 in people with Antiplatelet and Antithrombotic, run by Democritus University of Thrace at 1 site in Greece.
Trial summary
This study aims to evaluate the in vivo antithrombotic and anti-inflammatory effects of extra virgin olive oil daily consumption at recommended doses for 1 month compared to similar consumption of classic table olive oil, in the blood plasma and platelets of healthy donors Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Antiplatelet, Antithrombotic, Anti-Inflammatory Agents, Non-Steroidal
- What is being tested?
- Olive Oil 1 and Olive Oil 2
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 54 participants
- Where
- 1 siteGreece
- Study dates
- 1 Nov 2025to 30 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Not to have a pathological condition related to platelet and leukocyte activity
- Not to have a chronic pathological condition
- To have a Normal Body Mass Index (BMI) and waist circumference
- Not to take medications/supplements or any kind of other intervention that have anti-inflammatory and/or antithrombotic and/or antioxidant effects
Who cannot join
- To have a pathological condition related to platelet and leukocyte activity
- To have a chronic pathological condition
- Not to have a Normal Body Mass Index (BMI) and waist circumference
- To take medications/supplements/nutraceuticals or any kind of other intervention that have anti-inflammatory and/or antithrombotic and/or antioxidant effects
Trial locations and contacts
1 site in 1 country.
Greece1 site
Biochemistry Lab, Hephaestus Laboratory, School of Chemistry, Faculty of Sciences, Kavala University Campus, Democritus University of Thrace
Kavala, 65404
About this study
Official title: Study of the Anti-Inflammatory Health Benefits of "Argilos Extra Virgin Olive Oil" ("Healthy Argiloil")
This study aims to evaluate the in vivo antithrombotic and anti-inflammatory effects of extra virgin olive oil daily consumption at recommended doses for 1 month compared to similar consumption of classic table olive oil, in the blood plasma and platelets of healthy donors
Read the detailed description
Introduction: Thrombo-inflammatory manifestations are key pathophysiological mechanisms of cardiovascular diseases and are directly related to platelet activation and aggregation. Extra virgin olive oil, a key component of the Mediterranean diet, is rich in natural bioactives (e.g. unsaturated fatty acids, polar lipids, phenolic compounds, carotenoids and other pigments), which have been proposed to possess not only antioxidant activities, but mainly strong anti-inflammatory and antiplatelet properties, which contribute to the reduction of cardiovascular risk. However, to our knowledge, nutritional and biochemical evaluation of these properties through an in vivo intervention study has not been thoroughly conducted, especially for the cardioprotective benefits of consuming such an extra virgin olive oil against the main thrombo-inflammatory pathways, and compared to plain classic table olive oil.
Purpose: The purpose of this study was the qualitative characterization of a sample of extra virgin olive oil and the biochemical investigation of the effect of its daily consumption on platelet activation and on the mechanisms related to thrombo-inflammation compared to the effects observed by a similar consumption of classic table olive oil.
Materials and Methods: An in vivo dietary intervention study, randomised and single blinded (the volunteers did not know what type of olive oil they consumed) was performed on four arms:
In the 1st arm, 18 healthy volunteers consumed the nutritionally recommended daily dose (30 mL) of extra virgin olive oil daily for 28 days.
In the 2nd arm, 18 other healthy volunteers consumed the nutritionally recommended daily dose (30 mL) of plain classic table olive oil daily for 28 days.
In the 3rd arm, 9 healthy volunteers initially consumed the nutritionally recommended daily dose (30 mL) of extra virgin olive oil daily for 28 days and after a month washout period they then re-consumed the nutritionally recommended daily dose (30 mL) of plain classic table olive oil daily for another period of 28 days, in a crossover single blinded randomised design In the 4th arm, 9 healthy volunteers initially consumed the nutritionally recommended daily dose (30 mL) of plain classic table olive oil daily for 28 days and after a month washout period they then re-consumed the nutritionally recommended daily dose (30 mL) of extra virgin olive oil daily for another period of 28 days, in a crossover single blinded randomised design Blood samples were taken from all volunteers in all these 4 arms, on days 0 and 28 in each one of these interventions and platelet sensitization by various agonists was assessed just after blood sampling. Blood Plasma was stored at -20oC for further analysis Specifically the anti-inflammatory effects were expressed as the Effective Concentrations that induce 50% of platelet aggregation (EC50 values) by platelet-activating factor (PAF), the antithrombotic effects as the EC50 for Thrombin by using Thrombin Receptor Active Peptide (TRAP) and the antiplatelet effects as the EC50 values for ADP.
- Being tested
- Olive Oil 1, Olive oil (placebo) 1, Olive Oil 2, Olive oil (placebo) 2
- Keywords
- Anti-inflammatory, Antiplatelet, Antithrombotic, dietary intervention study, olive oil, platelet activating factor, thrombin, ADP, platelet aggregation, thrombo-inflammatory stimuli, Human Plasma, Human plasma rich in platelets, EC50 values, TEAC values, single blinded, crossover, randomized
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Olive Oil 1Other
Also called Dietary Intervention, Extra virgin olive oil (EVOO) consumption, Single Blinded, Randomised
1st arm: 18 healthy volunteers consumed 30 mL of extra virgin olive oil (EVOO) daily for 28 days. Blood samples and biochemical assays were conducted just before (day 0) and after (day 28) this dietary intervention
Olive oil (placebo) 1Other
Also called randomised, single blinded, plain classic table olive oil (CTOO) consumption, dietary intervention
2nd arm, 18 other healthy volunteers consumed 30 mL of plain classic table olive oil (CTOO) daily for 28 days.
Olive Oil 2Other
Also called single blinded, randomised, crossover, dietary intervention
3rd arm, 9 healthy volunteers initially consumed 30 mL of EVOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of CTOO daily for 28 days, in a crossover single blinded randomized design with the 3rd arm. Blood sampling and Biochemical Assays were conducted just before (day 0) and just after (day 28) each of these interventions
Olive oil (placebo) 2Other
Also called Dietary Intervnention, Crossover, Single Blinded, Randomised
4th arm, 9 healthy volunteers initially consumed 30 mL of CTOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of EVOO daily for 28 days, in a crossover single blinded randomized design with the 3rd arm. Blood sampling and Biochemical Assays were conducted just before (day 0) and just after (day 28) each of these interventions
| Study group | Role | What they receive |
|---|---|---|
| 1st arm: 18 healthy volunteers consumed 30 mL of extra virgin olive oil (EVOO) daily for 28 days | Experimental | Not described Receives: Other: Olive Oil 1 |
| 2nd arm, 18 healthy volunteers consumed 30 mL of plain classic table olive oil (CTOO) daily for 28 d | Active comparator | Not described Receives: Other: Olive oil (placebo) 1 |
| 3rd arm, 9 subjects consume 30 mL EVOO/d for 28d. After washout & crossover 30 mL of CTOO/d for 28d | Experimental | Not described Receives: Other: Olive Oil 2 |
| 4th arm, 9 subjects consume 30 mL CTOO/d for 28d. After washout & crossover 30 mL of EVOO/d for 28d | Active comparator | Not described Receives: Other: Olive oil (placebo) 2 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effective Concentration of 50% of platelet aggregation (EC50 value) for PAF
- The anti-inflammatory effects of the intervention assessed in platelets and plasma of blood samples from all volunteers are expressed as the Effective Concentrations that induce 50% of platelet aggregation (EC50 values) induced by platelet-activating factor (PAF), measured in nM concentration of PAF that can cause 50% of platelet aggregation.
Measured: Blood sampling and platelet sensitization by PAF is assessed just before (day 0) and just after (day 28) of each intervention in platelets and plasma of blood samples from all volunteers in all these 4 arms
Effective Concentration of 50% of platelet aggregation (EC50 value) for Thrombin
The antithrombotic effects of the intervention assessed in platelets and plasma of blood samples from all volunteers are expressed as the Effective Concentration that induce 50% of platelet aggregation (EC50 values) induced by the Thrombin Pathway, measured in μM concentration of Thrombin Receptor Active Peptide (TRAP) that can cause 50% of platelet aggregation
Measured: Blood sampling and platelet sensitization by TRAP is assessed just before (day 0) and just after (day 28) of each intervention in platelets and plasma of blood samples from all volunteers in all these 4 arms
Effective Concentration of 50% of platelet aggregation (EC50 value) for ADP
The antiplatelet effects of the intervention assessed in platelets and plasma of blood samples from all volunteers are expressed as the Effective Concentration that induce 50% of platelet aggregation (EC50 values) induced by the Adenosine 5' Diphosphate (ADP, measured in μM concentration of ADP that can cause 50% of platelet aggregation.
Measured: Blood sampling and platelet sensitization by ADP is assessed just before (day 0) and just after (day 28) of each intervention in platelets and plasma of blood samples from all volunteers in all these 4 arms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2026
- Study start1 Nov 2025
- Primary completion30 Sep 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for AntiplateletStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- in vivo dietary intervention study, randomised and single blinded with four arms: 1. st arm: 18 healthy volunteers consumed 30 mL of extra virgin olive oil (EVOO) daily for 28 days. 2. nd arm, 18 other healthy volunteers consumed 30 mL of plain classic table olive oil (CTOO) daily for 28 days. 3. rd arm, 9 healthy volunteers initially consumed 30 mL of EVOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of CTOO daily for 28 days, in a crossover single blinded randomised design with the 4th arm 4. th arm, 9 healthy volunteers initially consumed 30 mL of CTOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of EVOO daily for 28 days, in a crossover single blinded randomised design with the 3rd arm Biochemical assays for anti-inflammatory and antithrombotic effects were performed in platelets and plasma of blood samples from all volunteers at days 0 and 28 in each arm and intervention
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Democritus University of Thrace
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alexandros Tsoupras, Democritus University of Thrace
- Investigators
- Alexandros Tsoupras, Principal investigator, Democritus University of Thrace
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07784166
- Sponsor's protocol ID
- DUTh/EC/16218/176, 26-10-2025
- Other IDs
- KE83656
- Acronym
- HealthAgriloil
- Status last verified
- Aug 2026
- First submitted
- 4 Aug 2026
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: We might submit for publication all data and plan in an open access scientific journal, peer reviewed, in these fields of research
Publications
Sakshi Hans, Harishkumar Rajendran, Katie Shiels, Sushanta Kumar Saha, Alexandros Tsoupras, Ronan Lordan, Ioannis Zabetakis, The ex vivo and in vitro antithrombotic properties of fermented Irish ovine yogurt drink, in Proceedings of The 4th International Electronic Conference on Foods, 15 October-30 October 2023, MDPI: Basel, Switzerland, doi: 10.3390/Foods2023-15054
Lordan R, Tsoupras A, Zabetakis I. Investigation of Platelet Aggregation in Atherosclerosis. Methods Mol Biol. 2022;2419:333-347. doi: 10.1007/978-1-0716-1924-7_21.
PubMed 35237975Tsoupras A, Zabetakis I, Lordan R. Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function in vitro. MethodsX. 2018 Dec 26;6:63-70. doi: 10.1016/j.mex.2018.12.012. eCollection 2019.
PubMed 30619728Chrysikopoulou V, Rampaouni A, Koutsia E, Ofrydopoulou A, Mittas N, Tsoupras A. Anti-Inflammatory, Antithrombotic and Antioxidant Efficacy and Synergy of a High-Dose Vitamin C Supplement Enriched with a Low Dose of Bioflavonoids; In Vitro Assessment and In Vivo Evaluation Through a Clinical Study in Healthy Subjects. Nutrients. 2025 Aug 14;17(16):2643. doi: 10.3390/nu17162643.
PubMed 40871671
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Anti-Inflammatory Health Benefits of "Argilos Extra Virgin Olive Oil" ("Healthy Argiloil")
- ClinicalTrials.gov ID
- NCT07784166
- Acronym / sponsor ID
- HealthAgriloil / DUTh/EC/16218/176, 26-10-2025
- Keywords
- Anti-inflammatory, Antiplatelet, Antithrombotic, dietary intervention study, olive oil, platelet activating factor, thrombin, ADP
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Democritus University of ThraceUniversity, hospital or other
- Study start
- 1 Nov 2025 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 25 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the in vivo antithrombotic and anti-inflammatory effects of extra virgin olive oil daily consumption at recommended doses for 1 month compared to similar consumption of classic table olive oil, in the blood plasma and platelets of healthy donors
Detailed description
Introduction: Thrombo-inflammatory manifestations are key pathophysiological mechanisms of cardiovascular diseases and are directly related to platelet activation and aggregation. Extra virgin olive oil, a key component of the Mediterranean diet, is rich in natural bioactives (e.g. unsaturated fatty acids, polar lipids, phenolic compounds, carotenoids and other pigments), which have been proposed to possess not only antioxidant activities, but mainly strong anti-inflammatory and antiplatelet properties, which contribute to the reduction of cardiovascular risk. However, to our knowledge, nutritional and biochemical evaluation of these properties through an in vivo intervention study has not been thoroughly conducted, especially for the cardioprotective benefits of consuming such an extra virgin olive oil against the main thrombo-inflammatory pathways, and compared to plain classic table olive oil.
Purpose: The purpose of this study was the qualitative characterization of a sample of extra virgin olive oil and the biochemical investigation of the effect of its daily consumption on platelet activation and on the mechanisms related to thrombo-inflammation compared to the effects observed by a similar consumption of classic table olive oil.
Materials and Methods: An in vivo dietary intervention study, randomised and single blinded (the volunteers did not know what type of olive oil they consumed) was performed on four arms:
In the 1st arm, 18 healthy volunteers consumed the nutritionally recommended daily dose (30 mL) of extra virgin olive oil daily for 28 days.
In the 2nd arm, 18 other healthy volunteers consumed the nutritionally recommended daily dose (30 mL) of plain classic table olive oil daily for 28 days.
In the 3rd arm, 9 healthy volunteers initially consumed the nutritionally recommended daily dose (30 mL) of extra virgin olive oil daily for 28 days and after a month washout period they then re-consumed the nutritionally recommended daily dose (30 mL) of plain classic table olive oil daily for another period of 28 days, in a crossover single blinded randomised design In the 4th arm, 9 healthy volunteers initially consumed the nutritionally recommended daily dose (30 mL) of plain classic table olive oil daily for 28 days and after a month washout period they then re-consumed the nutritionally recommended daily dose (30 mL) of extra virgin olive oil daily for another period of 28 days, in a crossover single blinded randomised design Blood samples were taken from all volunteers in all these 4 arms, on days 0 and 28 in each one of these interventions and platelet sensitization by various agonists was assessed just after blood sampling. Blood Plasma was stored at -20oC for further analysis Specifically the anti-inflammatory effects were expressed as the Effective Concentrations that induce 50% of platelet aggregation (EC50 values) by platelet-activating factor (PAF), the antithrombotic effects as the EC50 for Thrombin by using Thrombin Receptor Active Peptide (TRAP) and the antiplatelet effects as the EC50 values for ADP.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 4
- Model description
- in vivo dietary intervention study, randomised and single blinded with four arms: 1. st arm: 18 healthy volunteers consumed 30 mL of extra virgin olive oil (EVOO) daily for 28 days. 2. nd arm, 18 other healthy volunteers consumed 30 mL of plain classic table olive oil (CTOO) daily for 28 days. 3. rd arm, 9 healthy volunteers initially consumed 30 mL of EVOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of CTOO daily for 28 days, in a crossover single blinded randomised design with the 4th arm 4. th arm, 9 healthy volunteers initially consumed 30 mL of CTOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of EVOO daily for 28 days, in a crossover single blinded randomised design with the 3rd arm Biochemical assays for anti-inflammatory and antithrombotic effects were performed in platelets and plasma of blood samples from all volunteers at days 0 and 28 in each arm and intervention
| Arm | Type | Receives |
|---|---|---|
| 1st arm: 18 healthy volunteers consumed 30 mL of extra virgin olive oil (EVOO) daily for 28 days | Experimental | Other: Olive Oil 1 |
| 2nd arm, 18 healthy volunteers consumed 30 mL of plain classic table olive oil (CTOO) daily for 28 d | Active comparator | Other: Olive oil (placebo) 1 |
| 3rd arm, 9 subjects consume 30 mL EVOO/d for 28d. After washout & crossover 30 mL of CTOO/d for 28d | Experimental | Other: Olive Oil 2 |
| 4th arm, 9 subjects consume 30 mL CTOO/d for 28d. After washout & crossover 30 mL of EVOO/d for 28d | Active comparator | Other: Olive oil (placebo) 2 |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Not to have a pathological condition related to platelet and leukocyte activity
- Not to have a chronic pathological condition
- To have a Normal Body Mass Index (BMI) and waist circumference
- Not to take medications/supplements or any kind of other intervention that have anti-inflammatory and/or antithrombotic and/or antioxidant effects
Key exclusion criteria (4 listed)
- To have a pathological condition related to platelet and leukocyte activity
- To have a chronic pathological condition
- Not to have a Normal Body Mass Index (BMI) and waist circumference
- To take medications/supplements/nutraceuticals or any kind of other intervention that have anti-inflammatory and/or antithrombotic and/or antioxidant effects
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Olive Oil 1Also: Dietary Intervention, Extra virgin olive oil (EVOO) consumption, Single Blinded, Randomised1st arm: 18 healthy volunteers consumed 30 mL of extra virgin olive oil (EVOO) daily for 28 days. Blood samples and biochemical assays were conducted just before (day 0) and after (day 28) this dietary intervention | Other | 1st arm: 18 healthy volunteers consumed 30 mL of extra virgin olive oil (EVOO) daily for 28 days |
| Olive oil (placebo) 1Also: randomised, single blinded, plain classic table olive oil (CTOO) consumption, dietary intervention2nd arm, 18 other healthy volunteers consumed 30 mL of plain classic table olive oil (CTOO) daily for 28 days. | Other | 2nd arm, 18 healthy volunteers consumed 30 mL of plain classic table olive oil (CTOO) daily for 28 d |
| Olive Oil 2Also: single blinded, randomised, crossover, dietary intervention3rd arm, 9 healthy volunteers initially consumed 30 mL of EVOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of CTOO daily for 28 days, in a crossover single blinded randomized design with the 3rd arm. Blood sampling and Biochemical Assays were conducted just before (day 0) and just after (day 28) each of these interventions | Other | 3rd arm, 9 subjects consume 30 mL EVOO/d for 28d. After washout & crossover 30 mL of CTOO/d for 28d |
| Olive oil (placebo) 2Also: Dietary Intervnention, Crossover, Single Blinded, Randomised4th arm, 9 healthy volunteers initially consumed 30 mL of CTOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of EVOO daily for 28 days, in a crossover single blinded randomized design with the 3rd arm. Blood sampling and Biochemical Assays were conducted just before (day 0) and just after (day 28) each of these interventions | Other | 4th arm, 9 subjects consume 30 mL CTOO/d for 28d. After washout & crossover 30 mL of EVOO/d for 28d |
Primary outcome
Effective Concentration of 50% of platelet aggregation (EC50 value) for PAF
Time frame: Blood sampling and platelet sensitization by PAF is assessed just before (day 0) and just after (day 28) of each intervention in platelets and plasma of blood samples from all volunteers in all these 4 arms
1. The anti-inflammatory effects of the intervention assessed in platelets and plasma of blood samples from all volunteers are expressed as the Effective Concentrations that induce 50% of platelet aggregation (EC50 values) induced by platelet-activating factor (PAF), measured in nM concentration of PAF that can cause 50% of platelet aggregation.
Effective Concentration of 50% of platelet aggregation (EC50 value) for Thrombin
Time frame: Blood sampling and platelet sensitization by TRAP is assessed just before (day 0) and just after (day 28) of each intervention in platelets and plasma of blood samples from all volunteers in all these 4 arms
The antithrombotic effects of the intervention assessed in platelets and plasma of blood samples from all volunteers are expressed as the Effective Concentration that induce 50% of platelet aggregation (EC50 values) induced by the Thrombin Pathway, measured in μM concentration of Thrombin Receptor Active Peptide (TRAP) that can cause 50% of platelet aggregation
Effective Concentration of 50% of platelet aggregation (EC50 value) for ADP
Time frame: Blood sampling and platelet sensitization by ADP is assessed just before (day 0) and just after (day 28) of each intervention in platelets and plasma of blood samples from all volunteers in all these 4 arms
The antiplatelet effects of the intervention assessed in platelets and plasma of blood samples from all volunteers are expressed as the Effective Concentration that induce 50% of platelet aggregation (EC50 values) induced by the Adenosine 5' Diphosphate (ADP, measured in μM concentration of ADP that can cause 50% of platelet aggregation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- BackgroundSakshi Hans, Harishkumar Rajendran, Katie Shiels, Sushanta Kumar Saha, Alexandros Tsoupras, Ronan Lordan, Ioannis Zabetakis, The ex vivo and in vitro antithrombotic properties of fermented Irish ovine yogurt drink, in Proceedings of The 4th International Electronic Conference on Foods, 15 October-30 October 2023, MDPI: Basel, Switzerland, doi: 10.3390/Foods2023-15054
- Background: PubMed 35237975Lordan R, Tsoupras A, Zabetakis I. Investigation of Platelet Aggregation in Atherosclerosis. Methods Mol Biol. 2022;2419:333-347. doi: 10.1007/978-1-0716-1924-7_21.
- Background: PubMed 30619728Tsoupras A, Zabetakis I, Lordan R. Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function in vitro. MethodsX. 2018 Dec 26;6:63-70. doi: 10.1016/j.mex.2018.12.012. eCollection 2019.
- Background: PubMed 40871671Chrysikopoulou V, Rampaouni A, Koutsia E, Ofrydopoulou A, Mittas N, Tsoupras A. Anti-Inflammatory, Antithrombotic and Antioxidant Efficacy and Synergy of a High-Dose Vitamin C Supplement Enriched with a Low Dose of Bioflavonoids; In Vitro Assessment and In Vivo Evaluation Through a Clinical Study in Healthy Subjects. Nutrients. 2025 Aug 14;17(16):2643. doi: 10.3390/nu17162643.
- Individual participant dataSharing planned: Undecided. We might submit for publication all data and plan in an open access scientific journal, peer reviewed, in these fields of research
Related trials for Antiplatelet
RecruitingPhase 4
The Bridging Antiplatelet Therapy With Cangrelor 2 Study
Coronary Arterial Disease (CAD)
Active, not recruiting
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
Thrombosis, Arterial Occlusive Diseases
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
RecruitingPhase 3
Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI
Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexandros Tsoupras principal investigator
Democritus University of Thrace
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Olive Oil 1 and Olive Oil 2 in people with Antiplatelet and Antithrombotic, run by Democritus University of Thrace at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effective Concentration of 50% of platelet aggregation (EC50 value) for PAF (time frame: Blood sampling and platelet sensitization by PAF is assessed just before (day 0) and just after (day 28) of each intervention in platelets and plasma of blood samples from all volunteers in all these 4 arms). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07784166, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.